What one share of Rein Therapeutics holds
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03.
Rein Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.30 |
| Dividends | $0.00 |
| Cash and investments | $0.10 |
| Book value | $0.64 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $0.00 | −$646.30 | $4.69 | −$589.15 | — | −$4,708 |
| 2016 | $0.00 | −$847.04 | — | — | $0.00 | −$5,171 |
| 2017 | $0.00 | −$60.85 | $0.38 | −$55.55 | $0.00 | $64.92 |
| 2018 | $0.00 | −$42.81 | $6.00 | −$43.90 | $0.00 | $26.58 |
| 2019 | $0.00 | −$23.94 | $0.12 | −$21.70 | $0.00 | $11.54 |
| 2021 | $0.00 | −$5.89 | $0.04 | −$5.38 | $0.00 | $9.69 |
| 2022 | $0.00 | −$6.02 | — | — | $0.00 | $4.10 |
| 2023 | $0.00 | −$3.42 | — | — | $0.00 | $20.12 |
| 2024 | $0.00 | −$3.51 | — | — | $0.00 | $2.51 |
| 2025 | $0.00 | −$1.96 | — | — | $0.00 | $0.61 |
Common questions about Rein Therapeutics
How much does one share of Rein Therapeutics earn?
Over the last 12 months, Rein Therapeutics lost $1.30 for each share.
Does Rein Therapeutics pay a dividend?
Rein Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Rein Therapeutics’s book value per share?
Rein Therapeutics’s book value is $0.64 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Rein Therapeutics have?
Each share of Rein Therapeutics has $0.10 of cash and investments, as of June 30, 2026.
Has Rein Therapeutics bought back shares?
Rein Therapeutics’s share count rose about 126898% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.